Biomedical Research

Purpose: To explore the influence of early application of Simvastatin on high-sensitivity C-reactive protein and fibrinolysis coagulation of unstable angina pectoris patients.

Method: 70 cases of unstable pectoris patients received and treated in our hospital during March 2011-2014 are taken as the research objects, and are divided into two groups randomly, 35 cases in each group. The patients of research group I are treated with simvastatin pills and that of research group II are treated with nitrate types and angiotensin invertase enzyme inhibitor; at the same time, 35 patients with no cardiac diseases are selected as the blank control group. The changes on blood lipid, highsensitivity C-reactive protein and fibrinolysis coagulation of the three groups before and after treatment are observed.

Results: The difference on blood lipid between research group I and research group II has no statistical significance (P>0.05). Compared with that of research group II, the high-sensitivity C-reactive protein of research group I is significantly reduced, with difference with statistical significance (q=9.25, P=0.02<0.05). On the aspect of coagulation fibrinolysis, the plasma blood coagulation factor VII, the fibrinogen and the plasminogen activator inhibitor of research group I are significantly reduced, and they have differences with statistical significance (P<0.05) when compared with that of research group II. At the same time, it has lower tissue-type plasminogen activator than that of research group II (F, P<0.05).

Conclusion: Early application of simvastatin can effectively reduce the blood lipid content and decrease the high-inflammation level of unstable angina pectoris patients; in addition, it can improve the anticoagulation level, helpful to the stability of plaques.

Author(s): Jing Bai, Junwei Zhang, Yanlei Ge, Jianjun Wang, Aibin Cheng
Abstract | Full-Text | PDF

Share this